Transgene expands neoantigen vaccine platform into lung cancer

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine - marketscreener.com

Transgene has announced the expansion of its myvac® platform into NSCLC via TG4070, an individualized neoantigen therapeutic vaccine. The company is leveraging its proprietary technology to target personalized antigens in this major solid tumor indication, marking a strategic broadening of its commercial pipeline beyond previous indications.